What are lipid nanoparticles (LNP)?

Lipid nanoparticles (LNPs) are nanoscale delivery vehicles composed of lipids that encapsulate therapeutic payloads, such as mRNA, siRNA or DNA.

• They protect fragile nucleic acids from degradation
• They enable cellular uptake and intracellular release
• They act as a nonviral alternative to gene delivery

What do LNPs actually do in drug delivery?

• Encapsulate nucleic acids or small molecules
• Transport payloads through biological barriers
• Release cargo inside target cells after endocytosis

Lipid nanoparticle technology

Lipid nanoparticle technology refers to the design, formulation and optimization of lipid-based carriers to deliver therapeutic payloads with precision and efficiency.

Key capabilities include:

• Tunable particle size, charge and composition
• Scalable manufacturing for clinical and commercial supply
• Flexibility across mRNA, ASO and RNAi applications

Lipid nanoparticle composition

LNP composition continues to diversify and can be tailored for specific use cases, cell types, environments or cargo types. Solid lipid nanoparticles are nanoscale particles composed of solid lipids. One key benefit is their ability to encapsulate various drugs, including hydrophilic, lipophilic and poorly soluble compounds. The solid lipid matrix provides a stable environment for drug incorporation, protecting it from degradation and improving its bioavailability.

LNPs - A safer, nonviral vector alternative in gene therapy

Modified viruses, such as lentivirus, herpes simplex virus, retrovirus and adeno-associated virus, have been extensively used as gene transfer vectors. Viruses facilitate effective gene transfer by leveraging their favorable cellular uptake and intracellular transportation mechanisms.

Challenges with viral vectors in gene transfer

Viral vectors possess certain inherent limitations, including

• Complex and costly manufacturing
• Restricted chances for repeated administrations due to acute inflammatory reactions and unintended immune responses

Additionally, some viral vectors may present risks of insertional mutagenesis, where foreign DNA becomes integrated into the host genome.

Advantages of nonviral vectors in gene delivery

Nonviral vectors have emerged as a safer and more flexible alternative to viral vectors, addressing the challenges associated with viral carriers. Nonviral gene delivery methods utilize synthetic or natural compounds and physical forces to transport DNA into cells. These materials are typically less toxic and provoke fewer immune responses compared to viral vectors. Moreover, nonviral approaches can achieve cell- or tissue-specificity by leveraging specific cell functions within chemical or biological carriers, while physical techniques enable precise targeting. An additional practical benefit of nonviral methods includes the possibility of repeated administration.

Lipid nanoparticles (LNPs) as an optimal nonviral platform

Among nonviral gene vectors, lipid nanoparticles (LNPs) represent an optimal platform for combining safety and efficacy in a single delivery system. LNPs have demonstrated strong capabilities to compact and deliver various nucleic acid molecules, ranging from small RNAs to large chromosomes, into cells. LNPs can be easily customized by incorporating targeting ligands on their surface.

Recent advancements in lipid-based gene delivery systems have significantly enhanced the effectiveness and expression levels of targeted genes, overcoming obstacles that previously limited the efficacy of nonviral delivery methods. The improved design of structure and activity has expanded the potential of LNPs in gene therapy for oncology and other diseases.

Nonviral methods are commonly considered less effective than viral methods and the duration of gene expression is often relatively short. Nevertheless, recent advancements indicate that certain physical methods for gene delivery have achieved levels of efficiency and expression duration that are clinically significant.

LNP manufacturing methods for mRNA delivery

Various methods are employed to produce lipid nanoparticles (LNPs) for mRNA delivery.

High-pressure homogenization

High-pressure homogenization involves subjecting a lipid-aqueous mixture to high pressure, forming LNPs with a narrow size distribution.

Hot homogenization

Hot homogenization utilizes heating and mixing lipids and the aqueous phase, followed by homogenization at an elevated temperature to create LNPs.

Cold homogenization

Cold homogenization involves mixing lipids and the aqueous phase at low temperatures prior to homogenization to generate small particles.

Other techniques

• Microemulsion method
• Solvent-based emulsification/evaporation
• Emulsification-solvent evaporation
• Sonication/ultrasound
• Solvent injection
• Phase reversal
• Membrane contraction

Each technique provides unique approaches for producing LNPs suitable for mRNA delivery.

Applications of LNPs in mRNA vaccines, ASO delivery and RNAi therapeutics

LNPs in mRNA-based vaccines: A crucial role in COVID-19 vaccination

• LNPs enable safe, effective delivery of mRNA to target cells, protecting it from degradation and aiding cellular uptake. This technology is vital to mRNA vaccines, such as those for COVID-19 and shows promise for gene therapies to treat genetic disorders.

LNPs in Antisense Oligonucleotide (ASO) Delivery

• LNPs have gained significant attention as a favored choice for delivering  antisense oligonucleotides (ASOs)  due to their unique properties. The precise formulation of LNPs crucially influences their biological behavior. By refining delivery parameters, researchers can create LNPs with specific traits that improve ASO delivery, including better stability, release and targeting.

Lipid nanoparticles in RNAi therapeutics: Targeted silencing for disease treatment

• RNA interference (RNAi) is a powerful therapeutic approach that targets and silences specific disease-causing genes. Researchers use lipid nanoparticles (LNPs), made of biodegradable lipids, to deliver RNAi therapies to target cells. This approach shows promising potential for treating many diseases, making it a key area in medicine and therapeutics.

Advancing Vaccine Performance with LNP-Based Delivery Systems

• Vaccine delivery via LNPs is a promising approach in vaccinology, serving as vehicles for adjuvants and antigens. Targeted delivery to immune cells enhances responses and may improve vaccine efficacy. mRNA vaccines, in particular, benefit from LNPs’ biocompatibility to protect mRNA from degradation. LNPs offer high encapsulation, controlled release and improved stability and immunogenicity. Careful design optimizes LNP-mRNA interactions for better cellular uptake and delivery.

Advantages of LNPs

Higher bioavailability and therapeutic efficacy in mRNA delivery

• LNPs effectively deliver and protect mRNA, increasing bioavailability and stability. They can be modified to target specific tissues, ensuring precise delivery and reducing off-target effects. LNPs can encapsulate a wide range of mRNA sequences, allowing for the development of diverse mRNA-based therapies, including vaccines and gene therapies. LNPs have lower immunogenicity than viral vectors, reducing unwanted immune responses. They offer a promising way to treat genetic disorders by delivering corrective mRNA, potentially curing some conditions.

LNPs in ASO delivery: Biocompatibility and shielding

• LNPs offer several advantages for ASO delivery, including biocompatibility, which means they are well tolerated and unlikely to cause adverse reactions. They are engineered to minimize immune interactions, reducing immune response risks that could interfere with therapy. LNPs protect ASOs from enzymatic degradation and nuclease attack in the extracellular environment, ensuring they stay intact and reach target cells effectively.

Advantages in RNAi: Protecting and facilitating uptake

• The advantage of using LNPs in delivering RNAi lies in their ability to protect the fragile RNAi cargo and facilitate its uptake by target cells. Moreover, some LNPs are designed to be rapidly eliminated from the body after delivering their cargo, reducing the risk of long-term accumulation and potential toxicity.

LNP-mediated vaccine delivery: Precision and swift response

• One of the key advantages of LNPs for vaccine delivery is the ability to modify their surface with targeting ligands, enabling specific delivery to immune cells or antigen-presenting cells, thereby enhancing the immune response. The use of mRNA-based vaccines in LNPs enables a swift response to emerging pathogens by allowing the rapid design and production of new vaccines based on their genetic sequences. These offer several advantages as delivery vehicles of antigens, including improved stability and controlled release of vaccine components.

Disadvantages of Lipid Nanoparticles LNPs

Liver tropism (off-target accumulation)

• What happens: LNPs preferentially accumulate in the liver following systemic administration

• Why it matters:

  • Limit delivery of extrahepatic tissues
  • May cause off-target effects or toxicity

• What’s driving it: Natural biodistribution and interaction with serum proteins

• Mitigation strategies:

  • Selective organ targeting (SORT) lipids
  • Charge modulation (internal/external lipid composition)
  • Surface functionalization with targeting ligands

Stability challenges (formulation sensitivity)

• What happens: LNP integrity is sensitive to environmental conditions

• Key stress factors:

  • pH fluctuations: structural disruption
  • Temperature changes: phase transitions or degradation
  • Lyophilization: aggregation or altered release profiles

• Why it matters:

  • Impacts cargo protection and release kinetics
  • Reduces shelf-life and manufacturability

• Mitigation strategies:

  • Optimized lipid composition
  • Cryoprotectants and stabilizing excipients
  • Improved formulation and storage protocols

PEG-related immunogenicity (circulation trade-offs)

• What happens: PEGylated lipids extend circulation time but can trigger immune responses

• Why it matters:

  • Formation of anti-PEG antibodies
  • Accelerated blood clearance (ABC effect)
  • Risk of hypersensitivity reactions

• Additional trade-off:

  • Higher PEG content: longer circulation but reduced cellular uptake

• Mitigation strategies:

  • Lower or optimized PEG density
  • Alternative stealth polymers
  • PEG structural modifications

Limited targeting specificity

• What happens: LNPs lack inherent tissue specificity

• Why it matters:

  • Broad biodistribution beyond the target site
  • Off-target interactions with healthy tissues

• Current limitation: Passive targeting dominates in most formulations

• Mitigation strategies:

  • Ligand-based targeting (e.g., antibodies, peptides)
  • Receptor-mediated uptake strategies
  • Tissue-specific lipid design

Future Perspectives of Lipid Nanoparticles

Lipid nanoparticles have significant potential in healthcare, including personalized medicine, cancer immunotherapy and vaccines. Targeted lipid nanoparticles are promising for CRISPR-Cas9 gene editing in cancer, enabling precise delivery to tumor cells for therapy. Solid tumors are key targets because of their hard-to-access nature and resistance, making them ideal for LNP targeting.